Drug resistance-related microRNAs in esophageal cancer

Bibliography

• Hong L, Li S, Han Y, Angiogenesis-related molecular targets in esophageal cancer. Expert Opin Investig Drugs 2011;20(5):637-44
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Li S, The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10(12):1693-701
   PubMed Web of Science ®Google Scholar
• Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr 2011;15(3):141-51
   PubMed Web of Science ®Google Scholar
• David S, Meltzer SJ. MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol 2011;11(6):612-16
   PubMed Web of Science ®Google Scholar
• Millan MJ. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr Opin Pharmacol 2011;11(1):11-22
   PubMed Web of Science ®Google Scholar
• Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110(3):483-95
   PubMed Web of Science ®Google Scholar
• Imanaka Y, Tsuchiya S, Sato F, MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011;56(4):270-6
   PubMed Web of Science ®Google Scholar
• Hamano R, Miyata H, Yamasaki M, Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011;17(9):3029-38
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63
   PubMed Web of Science ®Google Scholar
• Hummel R, Watson DI, Smith C, Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011;15(3):429-38
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Han Y, Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010;55(9):2545-51
   PubMed Web of Science ®Google Scholar
• Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010;17(8):523-31
   PubMed Web of Science ®Google Scholar
• Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr 2011;15(3):141-51
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007;26(5):311-20
   PubMed Web of Science ®Google Scholar
• Matsushima K, Isomoto H, Kohno S, MicroRNAs and esophageal squamous cell carcinoma. Digestion 2010;82(3):138-44
   PubMed Web of Science ®Google Scholar
• Senanayake U, Das S, Vesely P, MiR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 2012;33(5):1014-21
   PubMed Web of Science ®Google Scholar
• Mateescu B, Batista L, Cardon M, miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011;17(12):1627-35
   PubMed Web of Science ®Google Scholar
• Smith CM, Watson DI, Leong MP, miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol 2011;17(8):1036-44
   PubMed Web of Science ®Google Scholar
• Gonzales JC, Fink LM, Goodman OB Jr, Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9(1):39-45
   PubMed Web of Science ®Google Scholar
• Hu M, Xia M, Chen X, MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 2010;55(8):2365-72
   PubMed Web of Science ®Google Scholar
• Yaman Agaoglu F, Kovancilar M, Dizdar Y, Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011;32(3):583-8
   PubMed Web of Science ®Google Scholar
• Xu Y, Brenn T, Brown ER, Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012;106(3):553-61
   PubMed Web of Science ®Google Scholar
• Marchini S, Cavalieri D, Fruscio R, Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011;12(3):273-85
   PubMed Web of Science ®Google Scholar
• Chen ML, Liang LS, Wang XK. MiR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin Exp Metastasis 2012;29(5):457-69
   PubMed Web of Science ®Google Scholar
• Rokavec M, Wu W, Luo JL. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 2012;45(6):777-89
   PubMed Web of Science ®Google Scholar
• Wu Y, Xiao Y, Ding X, A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011;6(12):e29043
   PubMedGoogle Scholar
• Zheng B, Liang L, Wang C, MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 2011;17(24):7574-83
   PubMed Web of Science ®Google Scholar
• Liffers ST, Munding JB, Vogt M, MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest 2011;91(10):1472-9
   PubMed Web of Science ®Google Scholar
• Hummel R, Hussey DJ, Michael MZ, MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol 2011;18(1):253-60
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhao F, Wang ZN, Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep 2012;27(2):447-54
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Y, Huang Q, MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ 2011;18(11):1702-10
   PubMed Web of Science ®Google Scholar
• Robson JE, Eaton SA, Underhill P, MicroRNAs 296 and 298 are imprinted and part of the GNAS/Gnas cluster and miR-296 targets IKBKE and Tmed9. RNA 2012;18(1):135-44
   PubMed Web of Science ®Google Scholar
• Langenkamp E, Zwiers PJ, Moorlag HE, Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. Anticancer Drugs 2012;23(2):161-72
   PubMed Web of Science ®Google Scholar
• Yoon AR, Gao R, Kaul Z, MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. Nucleic Acids Res 2011;39(18):8078-91
   PubMed Web of Science ®Google Scholar
• Vaira V, Faversani A, Dohi T, miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 2012;31(1):27-38
   PubMed Web of Science ®Google Scholar
• Cazanave SC, Mott JL, Elmi NA, A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res 2011;52(8):1517-25
   PubMed Web of Science ®Google Scholar
• Urbich C, Kaluza D, Fromel T, MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012;119(6):1607-16
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011;30:55
   PubMed Web of Science ®Google Scholar
• Feng DD, Zhang H, Zhang P, Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011;15(10):2164-75
   PubMed Web of Science ®Google Scholar
• Spruck C MiR-27a regulation of SCF(Fbw7) in cell division control and cancer. Cell Cycle 2011;10(19):3232-3
   PubMed Web of Science ®Google Scholar
• Ma N, Li F, Li D, Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Mol Cell Biochem 2012;361(1-2):337-43
   PubMed Web of Science ®Google Scholar
• Patterson EE, Holloway AK, Weng J, MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011;117(8):1630-9
   PubMed Web of Science ®Google Scholar
• Veronese A, Lupini L, Consiglio J, Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010;70(8):3140-9
   PubMed Web of Science ®Google Scholar
• Bar-Eli M Searching for the 'melano-miRs': miR-214 drives melanoma metastasis. EMBO J 2011;30(10):1880-1
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Li S, Role of ZNRD1 (zinc ribbon domain-containing 1) in angiogenesis of leukaemia cells. Cell Biol Int 2011;35(4):321-4
   PubMed Web of Science ®Google Scholar
• Feng Y, Cao JH, Li XY, Inhibition of miR-214 expression represses proliferation and differentiation of C2C12 myoblasts. Cell Biochem Funct 2011;29(5):378-83
   PubMed Web of Science ®Google Scholar
• Derfoul A, Juan AH, Difilippantonio MJ, Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011;32(11):1607-14
   PubMed Web of Science ®Google Scholar
• van Mil A, Grundmann S, Goumans MJ, MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res 2012;93(4):655-65
   PubMed Web of Science ®Google Scholar
• Wang YS, Wang YH, Xia HP, MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev 2012;13(1):255-60
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Stoudemire J, Developing therapeutic microRNAs for cancer. Gene Ther 2011;18(12):1121-6
   PubMed Web of Science ®Google Scholar
• Gandellini P, Profumo V, Folini M, MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 2011;15(3):265-79
   PubMed Web of Science ®Google Scholar